VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

EAU 2022 | HERO: relugolix as an oral androgen-deprivation therapy in prostate cancer

Bertrand Tombal, MD, PhD, Université catholique de Louvain, Louvain, Belgium, discusses findings from the Phase III HERO study (NCT03085095), which evaluated relugolix, an gonadotropin-releasing hormone antagonist, against leuprolide in men with advanced prostate cancer. Relugolix is the first oral androgen-deprivation therapy and resulted in fewer cardiac events in patients with a previous cardiac history. The novel hormone antagonist additionally resulted in a higher proportion of patients with profound castrate levels, defines as a testosterone level of less than 20ng/dL. This interview took place at the European Association of Urology (EAU) Meeting 2022.

Disclosures

Prof. Tombal reports the conflicts of interest:
Advisor and/or investigator for AstraZeneca, MSD, Pfizer, Astellas

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter